González-Martín A, Pothuri B, Vergote I, et al. - In this randomized, double-blind, phase 3 trial, women with newly diagnosed advanced ovarian cancer were randomized in a 2:1 ratio to receive niraparib or placebo once daily following response to platinum-based chemotherapy in order to determine the effectiveness of niraparib in individuals with newly diagnosed advanced ovarian cancer following a response to first-line platinum-based chemotherapy. A total of 733 patients underwent randomization. It was discovered that among individuals with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly prolonged progression-free survival compared with those who received a placebo, irrespective of the presence or absence of homologous-recombination deficiency.